Trial Profile

Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipragliflozin (Primary) ; Sitagliptin
Indications Type 2 diabetes mellitus
Focus Therapeutic Use

Most Recent Events

22 Jun 2023 Primary endpoint has not been met. (Glycated hemoglobin), as per results published in the Diabetes, Obesity and Metabolism
22 Jun 2023 Results assessing Vascular and metabolic effects of ipragliflozin versus sitagliptin in type 2 diabetes treated with sulphonylurea and metformin , published in the Diabetes, Obesity and Metabolism
01 Oct 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com